Ranked #2,114 of 8,699 institutional investors
Cormorant Asset Management, LP
Boston, MA
$1.18B
US stock portfolio at live prices · today −$19.8M (−1.65%)
Live prices, last trade 10:50 AM ET
- Value at quarter end (Q3 2026)
- $1.49B
- Change from Q2 2026
- −$462.1M (−23.68%)
- Positions
- 52 · 12 new, 1 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$76.1M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPRAX 13.0%PBLS 10.9%EWTX 6.43%ERAS 5.78%RAPP 4.91%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PRAX Praxis Precision Medicines, Inc. | 500,000 | $153M | 13.0% | Reduced −22% |
| PBLS Parabilis Medicines, Inc. | 4,615,612 | $128M | 10.9% | Unchanged |
| EWTX Edgewise Therapeutics, Inc. | 1,860,000 | $75.7M | 6.43% | Reduced −26% |
| ERAS Erasca, Inc. | 5,000,000 | $68.0M | 5.78% | Reduced −17% |
| RAPP Rapport Therapeutics, Inc. | 2,457,521 | $57.8M | 4.91% | Reduced −8% |
| BLSM BlossomHill Therapeutics, Inc. | 3,614,034 | $53.1M | 4.51% | New |
| DNTH Dianthus Therapeutics, Inc. | 500,000 | $41.8M | 3.55% | Reduced −33% |
| ORKA Oruka Therapeutics, Inc. | 400,000 | $38.0M | 3.23% | Reduced −25% |
| ANL Adlai Nortye Group Ltd. | 3,978,229 | $34.8M | 2.96% | Unchanged |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 17,878,594 | $32.4M | 2.75% | Unchanged |
| MLTX MoonLake Immunotherapeutics | 2,855,433 | $31.4M | 2.67% | Reduced −11% |
| ETRA Electra Therapeutics, Inc. | 3,365,533 | $31.2M | 2.65% | New |
| ABVX ABIVAX Société Anonyme | 425,000 | $28.9M | 2.45% | Reduced −37% |
| ATTO Attovia Therapeutics, Inc. | 1,788,815 | $27.0M | 2.29% | New |
| LTGO Latigo Biotherapeutics, Inc. | 1,815,740 | $23.0M | 1.96% | New |
| IRD Opus Genetics, Inc. | 5,500,000 | $21.6M | 1.84% | New |
| MBX MBX Biosciences, Inc. | 375,000 | $19.5M | 1.66% | Reduced −32% |
| CLYM Climb Bio Inc | 2,106,000 | $19.4M | 1.65% | Unchanged |
| BBIO BridgeBio Pharma, Inc. | 250,000 | $19.3M | 1.64% | Reduced −55% |
| DRUG Bright Minds Biosciences Inc. | 800,000 | $16.8M | 1.43% | Reduced −11% |
| TNGX Tango Therapeutics, Inc. | 700,000 | $15.7M | 1.33% | Reduced −46% |
| AGMB AgomAb Therapeutics NV | 2,465,348 | $13.7M | 1.16% | Unchanged |
| FRNM Freenome, Inc. | 1,431,032 | $13.5M | 1.15% | New |
| ADRX ADARx Pharmaceuticals, Inc. | 962,898 | $13.5M | 1.15% | New |
| OLMA Olema Oncology, Inc. | 1,750,000 | $12.5M | 1.07% | Reduced −19% |
| SYRE Spyre Therapeutics, Inc. | 125,000 | $12.0M | 1.02% | Reduced −44% |
| BIOA BioAge Labs, Inc. | 2,240,605 | $10.1M | 0.86% | Reduced −6% |
| FTH Faeth Therapeutics, Inc. | 1,028,242 | $8.8M | 0.75% | Added +236% |
| ALMS Alumis Inc. | 2,075,000 | $8.7M | 0.74% | Reduced −37% |
| DFTX Definium Therapeutics, Inc. | 275,000 | $8.0M | 0.68% | Reduced −31% |
| AMLX Amylyx Pharmaceuticals, Inc. | 300,000 | $7.8M | 0.66% | Added +50% |
| ACRS Aclaris Therapeutics, Inc. | 1,750,000 | $6.1M | 0.52% | New |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 2,344,971 | $5.2M | 0.44% | Unchanged |
| JBIO Jade Biosciences, Inc. | 300,000 | $4.6M | 0.39% | New |
| KLRA Kailera Therapeutics, Inc. | 400,000 | $4.6M | 0.39% | Reduced −27% |
| CABA Cabaletta Bio, Inc. | 4,500,000 | $4.5M | 0.38% | Reduced −10% |
| TARS Tarsus Pharmaceuticals, Inc. | 50,000 | $3.8M | 0.32% | Reduced −50% |
| INBX Inhibrx Biosciences, Inc. | 50,000 | $3.7M | 0.31% | New |
| ELVN Enliven Therapeutics, Inc. | 75,000 | $3.5M | 0.30% | Reduced −50% |
| INSM Insmed Incorporated | 20,000 | $2.9M | 0.25% | Reduced −73% |
| IBIO iBio, Inc. | 3,570,000 | $2.9M | 0.25% | Unchanged |
| CUE Cue Biopharma, Inc. | 625,285 | $2.7M | 0.23% | New |
| BOLD Boundless Bio, Inc. | 940,000 | $2.2M | 0.18% | Reduced −6% |
| ODTX Odyssey Therapeutics, Inc. | 125,000 | $2.2M | 0.18% | Reduced −29% |
| EYPT EyePoint, Inc. | 5,750,000 | $1.5M | 0.12% | Reduced −18% |
| BRVE Braveheart Bio, Inc. | 70,000 | $1.4M | 0.12% | New |
| ARQT Arcutis Biotherapeutics, Inc. | 50,000 | $1.3M | 0.11% | Reduced −71% |
| PCVX Vaxcyte, Inc. | 15,000 | $863K | <0.1% | Reduced −70% |
| COGT Cogent Biosciences, Inc. | 30,000 | $817K | <0.1% | Reduced −70% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 15,000 | $640K | <0.1% | Reduced −70% |
| GPCR Structure Therapeutics Inc. | 30,000 | $498K | <0.1% | Reduced −60% |
| IRLA IRulya Therapeutics Inc. | 5,498 | $222K | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| ALT Altimmune, Inc. | 1,250,000 | $1.7M |